Anixa Biosciences Inc
Anixa Biosciences, Inc. (Nasdaq: ANIX) is a biotechnology company developing cancer therapies and vaccines. Its therapeutic program centers on liraltagene autoleucel, or lira-cel, a CAR-T cell therapy initially targeting ovarian cancer; a Phase 1 clinical trial is underway with Moffitt Cancer Center. Vaccine programs… From the company’s description.
Over the twelve months to Jul 31, 2026, Anixa Biosciences Inc reported a net loss of $10.47M. Operations used $7.38M in cash. In fiscal 2025, it reported a net loss of $11.03M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Anixa Biosciences Inc does
In the company’s own words
Anixa Biosciences, Inc. (Nasdaq: ANIX) is a biotechnology company developing cancer therapies and vaccines. Its therapeutic program centers on liraltagene autoleucel, or lira-cel, a CAR-T cell therapy initially targeting ovarian cancer; a Phase 1 clinical trial is underway with Moffitt Cancer Center. Vaccine programs include an investigational breast cancer vaccine targeting α-lactalbumin, an ovarian cancer vaccine targeting AMHR2-ED, and early-stage discovery of vaccines for lung, colon and prostate cancers. The company collaborates with Cleveland Clinic on vaccine development and licenses technology from The Wistar Institute for lira-cel. Its breast cancer vaccine completed a Phase 1 trial in 2025, while the ovarian vaccine remains in preclinical development. Anixa also conducts limited legacy patent-licensing activities; its therapeutic and vaccine programs have not generated revenue. As of October 31, 2025, the company had four full-time employees and subsidiaries. It aims to license technologies to pharmaceutical companies for development and commercialization. Its website is www.anixa.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN JOSE, CA
- Fiscal year end
- October
- CIK
- 715446
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Anixa Biosciences Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Anixa Biosciences Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Anixa Biosciences Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Anixa Biosciences Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Anixa Biosciences Inc's last four quarterly filings that the numbers alone won't show?”